4-(2-t-butoxycarbonamidoethyl)phenoxyacetic acid | 64318-33-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-t-butoxycarbonamidoethyl)phenoxyacetic acid
• 英文别名: [4-(2-tert-Butoxycarbonylamino-ethyl)-phenoxy]-acetic acid；2-[4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]phenoxy]acetic acid
• CAS: 64318-33-8
• 化学式: C₁₅H₂₁NO₅
• 分子量: 295.335
• InChiKey: SBLCBWNCGZUFJX-UHFFFAOYSA-N

物化性质

• 沸点：
  470.1±30.0 °C(Predicted)
• 密度：
  1.170±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(2-t-butoxycarbonamidoethyl)phenoxyacetic acid 在 盐酸 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 2-((2-((4-(2-((2-(2-azidoethoxy)ethyl)amino)-2-oxoethoxy)phenethyl)amino)-2-oxoethyl)(4-methoxybenzyl)amino)-N-methyl-N-((1R,2S)-1-phenyl-1-(prop-2-yn-1-yloxy)propan-2-yl)acetamide
  参考文献：
  名称：

  Comparison of diffusion coefficients for matched pairs of macrocyclic and linear molecules over a drug-like molecular weight range

  摘要：

  通过核磁共振波谱法比较了一系列紧密匹配的大环和线性分子对的扩散系数。大环系列的设计既与通常用于类药物分子的分子量范围重叠，又有所扩展。每个线性分子代表了其相应大环分子的碳解裂变，旨在最小化功能和物理化学性质的差异。每个分子系列均采用铜催化的叠氮-炔环加成（CuAAC）反应，在流动体系中使用铜管进行制备。在整个研究分子量范围内，大环系列始终展现出更高的扩散性。大环和线性类似物之间扩散系数的倍数差异似乎与溶剂粘度或介电环境无关。

  DOI：

  10.1039/c1ob05996c
• 作为产物：
  描述：

  对羟基苯乙腈 在 sodium hydroxide 、 sodium tetrahydroborate 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-(2-t-butoxycarbonamidoethyl)phenoxyacetic acid
  参考文献：
  名称：

  Structure–activity relationship studies of a bisbenzimidazole-based, Zn2+-dependent inhibitor of HCV NS3 serine protease

  摘要：

  A survey of isosteric replacements of the phosphonoalanine side chain coupled with a process of conformational constraint of a bisbenzimidazole-based, Zn2+-dependent inhibitor of hepatitis C virus (HCV) NS3 serine protease resulted in the identification of novel series of active compounds with extended side chains. However, Zn2+-dependent HCV NS3 inhibition was relatively insensitive to the structural variations examined but dependent on the presence of negatively charged functionality. This result was interpreted in the context of an initial electrostatic interaction between protease and inhibitor that is subsequently consolidated by Zn2+, with binding facilitated by the featureless active site and proximal regions of the HCV NS3 protein. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00457-7

文献信息

• C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases
  申请人：——

  公开号：US20020042376A1

  公开（公告）日：2002-04-11

  This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

  这项发明涉及新型的oxamyl二肽ICE/ced-3家族抑制剂化合物。该发明还涉及含有这些化合物的药物组合物，以及在治疗患有炎症性、自身免疫和神经退行性疾病的患者中使用这些组合物，用于预防缺血性损伤，并用于保存即将进行移植手术的器官。
• Synthesis of 5-Iodo-1,2,3-triazole-Containing Macrocycles Using Copper Flow Reactor Technology
  作者：Andrew R. Bogdan、Keith James

  DOI：10.1021/ol201567s

  日期：2011.8.5

  A new macrocyclization strategy to synthesize 12- to 31-membered 5-iodo-1,2,3-triazole-containing macrocycles is described. The macrocycles have been generated using a simple and efficient copper-catalyzed cycloaddition in flow under environmentally friendly conditions. This methodology also permits the facile, regioselective synthesis of 1,4,5-trisubstituted-1,2,3-triazole-containing macrocyles using

  描述了一种新的大环合成策略，可以合成12到31元的含5-碘-1,1,2,3-三唑的大环。大环化合物是在环境友好的条件下使用简单有效的铜催化环加成反应生成的。该方法还允许使用钯催化的交叉偶联反应，容易地，区域选择性地合成含1,4,5-三取代-1,2,3-三唑的大环。
• (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases
  申请人：Idun Pharmaceuticals, Inc.

  公开号：US20030232788A1

  公开（公告）日：2003-12-18

  This invention is directed to novel (substituted)acyl dipeptidyl ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

  这项发明涉及新型（取代）酰基二肽酶ICE/ced-3家族抑制剂化合物。该发明还涉及含有这些化合物的药物组合物，以及将这些组合物用于治疗患有炎症、自身免疫和神经退行性疾病的患者，预防缺血性损伤，并保护即将进行移植手术的器官。
• C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
  申请人：——

  公开号：US20020028774A1

  公开（公告）日：2002-03-07

  This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

  这项发明涉及新颖的oxamyl二肽ICE/ced-3家族抑制剂化合物。该发明还涉及含有这些化合物的药物组合物，以及将这些组合物用于治疗患有炎症、自身免疫和神经退行性疾病的患者，预防缺血性损伤，并保护将要进行移植手术的器官。
• [EN] (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES<br/>[FR] INHIBITEURS ACYLE(SUBSTITUE) DIPEPTIDYLE DE LA FAMILLE ICE/ced-3 DES CYSTEINES PROTEASES
  申请人：IDUN PHARMACEUTICALS INC

  公开号：WO2000023421A1

  公开（公告）日：2000-04-27

  This invention is directed to novel (substituted)acyl dipeptidyl ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

  本发明涉及新型（取代）酰基二肽酶ICE / ced-3家族抑制剂化合物。本发明还涉及含有这些化合物的制药组合物，以及将这些组合物用于治疗患有炎症，自身免疫和神经退行性疾病的患者，预防缺血性损伤，并用于保护即将进行移植手术的器官。